Article summary
The European Medicines Agency (EMA) has waived all fees for scientific advice for academia developing medicines for rare diseases. The decision to waive fees was brought on by feedback from academia that fees for protocol assistance represents a barrier to engaging with the EMA. The EMA has included academia in the list of organisations eligible for free protocol assistance as of 19 June 2020. Eligible applicants include ‘public or private higher education establishments awarding academic degrees, public or private non-profit research organisations whose primary mission is to pursue research, and international European interest organisations.’
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial